A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy

Abstract

The overall goal of this project remains to bring epigenetic therapy strategies to have major impact forthe management of advanced ovarian cancer (OC). In the first year, we have made exciting advances for this purpose and especially for the concept of utilizing low dose epigenetic therapy to target DNA demethylation and histone deacetylase inhibition (HDACi) to maximize responses to immune checkpoint therapy. We identified, from studies of multiple OC cell lines how low doses of the DNA demethylation agents, azacytidine (AZA) and deoxy-azacytidine (DAC) induce a deep immune attraction signature.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2015
Accession Number
AD1013500

Entities

People

  • Stephen B. Baylin

Organizations

  • Johns Hopkins University

Tags

DTIC Thesaurus Topics

  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Genetics
  • Health Services
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Stem Cells

Fields of Study

  • Biology

Readers

  • Molecular and genetic basis of cancer.
  • Oncology (Cancer Research).
  • Research Science/Academic Research

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech